(Q46701419)

English

Pimecrolimus cream 1% in the long-term management of adult atopic dermatitis: prevention of flare progression. A randomized controlled trial

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/18341665

Pimecrolimus cream 1% in the long-term management of adult atopic dermatitis: prevention of flare progression. A randomized controlled trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/18341665

atopic dermatitis

1 reference

based on heuristic

inferred from title

author name string

H Gollnick

1

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/18341665

R Kaufmann

2

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/18341665

D Stough

3

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/18341665

H Heikkila

4

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/18341665

K Andriano

5

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/18341665

A Grinienko

6

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/18341665

P Jimenez

7

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/18341665

Pimecrolimus Cream 1% in (adult) Eczema: Prevention of Progression Multicentre Investigator Study Group

8

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/18341665

language of work or name

0 references

publication date

13 March 2008

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/18341665

British Journal of Dermatology

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/18341665

158

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/18341665

5

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/18341665

1083-1093

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/18341665

Cost of atopic dermatitis and eczema in the United States

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2008.08484.X

21 January 2018

Quality of life in atopic dermatitis.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2008.08484.X

21 January 2018

Treatment of atopic dermatitis and impact on quality of life: a review with emphasis on topical non-corticosteroids

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2008.08484.X

21 January 2018

Actigraphy assessment of sleep disturbance in patients with atopic dermatitis: an objective life quality measure

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2008.08484.X

21 January 2018

Practical management of atopic eczema

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2008.08484.X

21 January 2018

Atopic dermatitis: new insights and opportunities for therapeutic intervention

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2008.08484.X

21 January 2018

Current management of atopic dermatitis and interruption of the atopic march

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2008.08484.X

21 January 2018

The new topical ascomycin derivative SDZ ASM 981 does not induce skin atrophy when applied to normal skin for 4 weeks: a randomized, double-blind controlled study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2008.08484.X

21 January 2018

Corticosteroid-induced atrophy and barrier impairment measured by non-invasive methods in human skin

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2008.08484.X

21 January 2018

Short-term glucocorticoid treatment compromises both permeability barrier homeostasis and stratum corneum integrity: inhibition of epidermal lipid synthesis accounts for functional abnormalities

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2008.08484.X

21 January 2018

Adverse effects of topical glucocorticosteroids

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2008.08484.X

21 January 2018

Steroid addiction

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2008.08484.X

21 January 2018

Morphologic Investigations on the Rebound Phenomenon After Corticosteroid-Induced Atrophy in Human Skin

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2008.08484.X

21 January 2018

Topical corticosteroid phobia in patients with atopic eczema

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2008.08484.X

21 January 2018

Pimecrolimus -- an anti-inflammatory drug targeting the skin

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2008.08484.X

21 January 2018

Pimecrolimus cream in the long-term management of atopic dermatitis in adults: a six-month study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2008.08484.X

21 January 2018

Long-term safety and tolerability of pimecrolimus cream 1% and topical corticosteroids in adults with moderate to severe atopic dermatitis.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2008.08484.X

21 January 2018

Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescents

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2008.08484.X

21 January 2018

Long-term management of atopic dermatitis in infants with topical pimecrolimus, a nonsteroid anti-inflammatory drug.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2008.08484.X

21 January 2018

Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2008.08484.X

21 January 2018

The benefit of pimecrolimus (Elidel, SDZ ASM 981) on parents' quality of life in the treatment of pediatric atopic dermatitis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2008.08484.X

21 January 2018

Safety and efficacy of nonsteroid pimecrolimus cream 1% in the treatment of atopic dermatitis in infants

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2008.08484.X

21 January 2018

Onset of action of pimecrolimus cream 1% in the treatment of atopic eczema in infants

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2008.08484.X

21 January 2018

Long-term control of atopic dermatitis with pimecrolimus cream 1% in infants and young children: a two-year study.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2008.08484.X

21 January 2018

First experience of topical SDZ ASM 981 in children with atopic dermatitis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2008.08484.X

21 January 2018

Low systemic exposure in infants with atopic dermatitis in a 1-year pharmacokinetic study with pimecrolimus cream 1%*.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2008.08484.X

21 January 2018

Systemic exposure, tolerability, and efficacy of pimecrolimus cream 1% in atopic dermatitis patients

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2008.08484.X

21 January 2018

Long-term treatment of atopic dermatitis with pimecrolimus cream 1% in infants does not interfere with the development of protective antibodies after vaccination

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2008.08484.X

21 January 2018

Immunomodulation and safety of topical calcineurin inhibitors for the treatment of atopic dermatitis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2008.08484.X

21 January 2018

Use of pimecrolimus cream 1% (Elidel) in the treatment of atopic dermatitis in infants and children: the effects of ethnic origin and baseline disease severity on treatment outcome

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2008.08484.X

21 January 2018

Intermittent dosing of fluticasone propionate cream for reducing the risk of relapse in atopic dermatitis patients

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2008.08484.X

21 January 2018

A new approach to the analysis of clinical drug trials with withdrawals.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2008.08484.X

21 January 2018

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2008.08484.X

21 January 2018

Identifiers

10.1111/J.1365-2133.2008.08484.X

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/18341665

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/18341665

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46701419&oldid=2127359019"